Navigation Links
Chiltern Appoints Jane Turner as Late Phase Director for Europe
Date:2/27/2009

LONDON, Feb. 27 /PRNewswire/ -- Chiltern a leading global clinical research organization announced today that it has appointed Ms. Jane Turner to the post of Director, Late Phase, Europe.

Ms. Turner brings over 24 years of experience to her new position in Chiltern's global Late Phase Organization. Ms. Turner previously held executive positions in both CRO and Pharmaceutical companies, enabling her to acquire considerable knowledge of the operational side of management in both industries. In her most recent position, Jane worked on the management of Late Phase studies with focus on a European setting. Jane's operational base will be Chiltern's global headquarters in Slough, United Kingdom. Jane received a B.Pharm from the University of Nottingham and a Diploma in Clinical Science from the University of Wales.

"I am pleased that Jane chose to bring her expertise and experience to Chiltern," said Steve Albrecht, Chiltern's Senior Director, Late Phase (global). "Our global Late Phase Team has grown significantly over the past few years and Jane's extensive business and operational experience will help us bring innovative and high quality solutions to exceed our sponsors varied Late Phase needs," Steve added.

"I am delighted to join Steve and the global Late Phase group at Chiltern," Jane Turner stated. "There is an increasing demand from both the regulatory authorities and the public for Late Phase studies especially in the domain of drug safety. These requests can negatively affect our sponsors with added costs and time delays; therefore it is imperative that CROs continue to look for innovative solutions while preserving the integrity of the data and the safety of the subjects."

"Jane adds significant strength to our global Late Phase Team," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "We are experiencing increased demand for Chiltern's Late Phase services utilizing our expertise, our global Call Centers and our web-based data collection platforms to provide sponsors with the unique services required for their marketed products. We are looking forward to Jane's keen insights as we customize our services to meet the needs of the key stakeholders, ie, our sponsors, the regulatory authorities, and the patients."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern has 1,400 employees located in 24 offices throughout Europe, the Americas and Asia. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

    For More Information Contact:
    Catherine Lemercier                       Richard Baptista
    Chiltern International, Inc.              Chiltern International Ltd.
    2111 Palomar Airport Road                 171 Bath Road
    Suite 200                                 Slough
    Carlsbad                                  Berkshire
    CA 92011                                  SL1 4AA
    USA                                       UNITED KINGDOM
    Tel: 1 (760) 707 5025                     Tel: +44 (0) 1753 512 000
    Fax: 1 (760) 707 5022                     Fax: +44 (0) 1753 511 116
    Email:                                    Email:
    Catherine.Lemercier@chiltern.com          Richard.Baptista@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chilterns Resourcing Solutions Division Appoints New Managers to Spain and the United Kingdom
2. Chiltern and EPS INTERNATIONAL Enter Into a Global Partnership
3. Chiltern Enhances Its Portfolio of Electronic Data Capture (EDC) Services With the Addition of Hosting and eCRF Design Services for DataLabs (by ClinPhone) and Medidata Rave(R) Certification
4. Chiltern Expands Its Global Reach to Latin America
5. Chiltern Announces New Expansion in Portugal
6. Chiltern Opens a New Office in Russia
7. Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas, April 14 - 16, 2008.
8. Chiltern Wins Top Prize
9. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
10. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
11. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: